A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
NCT ID: NCT00323037
Last Updated: 2023-03-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
318 participants
INTERVENTIONAL
2006-03-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg
NCT00272805
Pilot Study of COR-1 in Heart Failure
NCT01391507
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
NCT00259038
CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices
NCT03217331
A Study of CLR325 in Chronic Stable Heart Failure Patients.
NCT02696967
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Carvedilol (Coreg IR) is a multiple action adrenergic receptor blocker with alpha 1, beta 1 and beta 2 receptor blockade properties. The beta-adrenergic properties are non-selective for beta 1 and beta 2 adrenergic receptors. Coreg IR, administered twice daily, is marketed in the United States for long term treatment of mild-moderate hypertension, mild to severe heart failure and subjects surviving an acute myocardial infarction with left ventricular dysfunction with or without symptomatic heart failure.
Coreg IR significantly reduces all cause mortality and the need for cardiovascular hospitalization \[Packer, 1996a; Packer, 1996b; Colucci, 1996; Cohn, 1997; Olsen, 1995; Sharpe 1997\]. The effect of Coreg is dose dependent \[Bristow, 1996\]. In subjects treated long term after an acute myocardial infarction (MI) complicated by left ventricular systolic dysfunction, Coreg IR reduced the frequency of all-cause and cardiovascular mortality, and recurrent non-fatal MIs. These beneficial effects are additional to those of evidence-based treatments for acute MI, including ACE inhibitors \[Dargie, 2001\].
Left Ventricular End Systolic Volume Index (LVESVI) is an important measure of ventricular function and remodeling in the evaluation of heart failure. In controlled clinical trials, Coreg IR, administered twice daily, has reduced LVESVI in subjects with ischemic heart failure. An echocardiography substudy of the Australia-New Zealand Trial \[Doughty, 1997\], evaluated left ventricular remodeling in 123 subjects with ischemic heart failure with an LVEF \< 45 randomized to carvedilol or placebo. The LVESVI was reduced by 6.2 + 1.6 ml/m2 after 6 months and 8.7 + 2.6 ml/m2 after 12 months of carvedilol therapy compared to the placebo treated subjects. Metra et al \[Metra, 2000\] observed the favorable effects of carvedilol compared with metoprolol on LVEF, LV stroke volume, and pulmonary artery pressure despite similar effects on cardiovascular outcome. Both groups also showed significant decreases in LV systolic volume. Doughty et al \[Doughty, 2004\] observed the favorable effects of carvedilol on LV remodeling, with improved LV end-systolic volume and ejection fraction, after 6 months of treatment.
Carvedilol phosphate CR (Coreg CR) is an approved, modified release, once-daily formulation of carvedilol that is hoped to provide an advance in patient care through improved compliance with prescribed dose.
The clinical experience with various formulations of Coreg CR is limited to eight single dose studies in healthy subjects and one repeated dose study in subjects with hypertension. In total 230, adult subjects have received at least one dose of Coreg IR or one of several CR formulations across nine studies. The subjects ranged in age from 18 to 63 years; 62% were male and 69% were white. The various formulations of Coreg CR capsules were safe and well tolerated in single dose pharmacokinetic studies in doses ranging from 6.25 to 60 mg in healthy subjects. The most common adverse events were headache, dizziness and orthostatic hypotension and are all known adverse events following administration of Coreg IR \[GSK Study 386, 388, 399, 400, 402, 907\].
This study will be the first controlled clinical study investigating the efficacy of treatment with Coreg CR formulation \[Coreg CR filled with 7.5 mg of carvedilol phosphate immediate release (IRp) microparticles, 22.5 mg of carvedilol phosphate Micropump IIa MR microparticles, and 30 mg of carvedilol phosphate Micropump IIc MR microparticles\] compared to Coreg IR evaluating LVESVI in subjects with stable chronic heart failure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
carvedilol immediate release
Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
2
carvedilol controlled release
Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carvedilol controlled release
Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
carvedilol immediate release
Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age at the time informed consent is signed
* Stable, chronic, mild to severe heart failure as defined as subjects with symptoms of heart failure who do not require IV diuretics, inotropes, or vasodilators or those that require support with a left ventricular assist device
* Angiotensin converting enzyme inhibitors or angiotensin receptor blockers should be prescribed to all patients with HF due to LV systolic dysfunction with reduced LVEF unless contraindicated or intolerant to use
* At screening, subject has an LVEF \< 40 as measured by 2-D echocardiography
* Willing to provide written informed consent
Exclusion Criteria
* Acute ischemic coronary event or coronary revascularization (PTCA, CABG, thrombolysis) within 1 week of screening echocardiography
* Scheduled or expected to be scheduled coronary revascularization within 4 weeks
* Unstable angina (angina characterized by sudden changes in the severity or length of angina attacks or a decrease in level of exertion that precipitates an episode
* Uncorrected primary obstructive or severe regurgitant valvular disease, nondilated (restrictive) or hypertrophic cardiomyopathies
* Uncontrolled ventricular arrhythmias (symptomatic or sustained ventricular arrhythmias not controlled with antiarrhythmic therapy or an implantable defibrillator)
* Current treatment of calcium channel blockers except for long acting dihydropyridines
* Current treatment on any Class I or III antiarrhythmic, except amiodarone
* History of sick sinus syndrome unless a pacemaker is in place
* Second or third degree heart block unless a pacemaker is in place
* Current clinical evidence of obstructive pulmonary disease (e.g., asthma or bronchitis) requiring inhaled or oral bronchodilator or steroid therapy; or having a history of bronchospastic disease not undergoing active therapy in whom, in the investigator's opinion, treatment with study medication could provoke bronchospasm
* Expected biventricular pacemaker placement within 8 months of enrollment
* Resting systolic blood pressure \<90 mmHg (based on the average of 3 readings
* Resting heart rate \<50 beats per minute (bpm) (based on the average of 3 readings)
* Current decompensated heart failure
* Elevated liver enzymes (i.e., ALT or AST levels greater than 3 times upper limit of normal)
* History of drug sensitivity or allergic reaction to alpha or beta-blockers
* Contraindication or intolerance to beta-blockers
* Pregnant or lactating women and women planning to become pregnant. NOTE: Female subjects must be post-menopausal (i.e., no menstrual period for a minimum of 6 months prior to screening), surgically sterilized, using a double barrier method contraceptive, or using Depo-Provera or implanted contraceptives for at least one month prior to screening and agree to continue to use the same contraceptive method throughout the study.
* Use of an investigational drug within 30 days of enrollment
* Participation in an investigational device trial within 30 days of enrollment
* Known drug or alcohol abuse 1 year prior to enrollment
* In the opinion of the investigator the subject is known to be noncompliant with prescribed medication regimen
* Has any systemic disease, including cancer, with reduced life expectancy (\<12 months)
* Has a history of psychological illness/condition that interferes with ability to understand or complete requirements of the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CTI Clinical Trial and Consulting Services
OTHER
GlaxoSmithKline
INDUSTRY
CTI-1, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barry Greenberg, MD
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology Associates
Mobile, Alabama, United States
Mobile Heart Specialists
Mobile, Alabama, United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
Scottsdale Cardiovascular Research Institute
Scottsdale, Arizona, United States
South West Heart
Tucson, Arizona, United States
Inland Heart Doctors Medical Group
Corona, California, United States
Rancho Los Amigos USC
Downey, California, United States
William Bowden, DO Private Practice
Healdsburg, California, United States
Merced Heart Associates
Merced, California, United States
Sutter Memorial Hospital
Sacramento, California, United States
Southern California Cardiology Medical Group, Inc.
San Diego, California, United States
Medvin Clinical Research
Van Nuys, California, United States
Aurora Denver Cardiology Associates
Denver, Colorado, United States
Medical Center of the Rockies Foundation
Loveland, Colorado, United States
Bay Area Cardiology
Brandon, Florida, United States
Clearwater Cardiovascular and Interventional Consultants
Clearwater, Florida, United States
White-Wilson Medical Center, PA
Fort Walton Beach, Florida, United States
South Florida International Cardiology Consultants, Inc.
Miami, Florida, United States
Palm Beach Cardiology
Palm Beach Gardens, Florida, United States
Cardiac Disease Specialists, PC
Atlanta, Georgia, United States
Harbin Clinic
Rome, Georgia, United States
North Shore Cardiovascular Research Consortium
Bannockburn, Illinois, United States
Saint Francis Hospital
Evanston, Illinois, United States
Illinois Heart and Vascular
Hinsdale, Illinois, United States
HeartCare Midwest
Peoria, Illinois, United States
Rockford Cardiology Research Foundation
Rockford, Illinois, United States
Prairie Cardiovascular Consultants
Springfield, Illinois, United States
The Care Group LLC
Indianapolis, Indiana, United States
River Cities Cardiology
Jeffersonville, Indiana, United States
Iowa Heart Center
West Des Moines, Iowa, United States
Mid-America Cardiology
Kansas City, Kansas, United States
Via Christi Research, Inc.
Wichita, Kansas, United States
Comprehensive Cardiology Associates
Florence, Kentucky, United States
Cardiovascular Associates
Louisville, Kentucky, United States
Louisville Cardiology Medical Group
Louisville, Kentucky, United States
One Heart, LLC
Baltimore, Maryland, United States
Minnesota Heart Clinic
Edina, Minnesota, United States
Hennepin County Medical Center
Minneapolis, Minnesota, United States
Regions Hospital Cardiology Research
Saint Paul, Minnesota, United States
St. Paul Cardiology
Saint Paul, Minnesota, United States
Cardiology Associates Research, LLC
Tupelo, Mississippi, United States
Rocky Mountain Heart & Lung
Kalispell, Montana, United States
Diagnostic and Clinical Cardiology
West Orange, New Jersey, United States
University of New Mexico
Albuquerque, New Mexico, United States
Albany Associates in Cardiology
Albany, New York, United States
Buffalo Heart Group, LLP
Buffalo, New York, United States
Long Island Heart Associates
Mineola, New York, United States
New York Cardiovascular Associates
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
South Bay Cardiovascular Associates
West Islip, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
LeBauer Cardiovascular Research Foundation
Greensboro, North Carolina, United States
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
Sterling Research Group Ltd.
Cincinnati, Ohio, United States
The Lindner Clinical Trial Center
Cincinnati, Ohio, United States
University Hospital
Cincinnati, Ohio, United States
Northwest Ohio Cardiology Consultants
Toledo, Ohio, United States
Oklahoma Cardiovascular Research Group
Oklahoma City, Oklahoma, United States
Samaritan Cardiology
Corvallis, Oregon, United States
Blair Medical Associates
Altoona, Pennsylvania, United States
Tri-State Medical Group
Beaver, Pennsylvania, United States
Central Bucks Specialists
Doylestown, Pennsylvania, United States
Cardiology Consultants of Philadelphia
Philadelphia, Pennsylvania, United States
Mid State Medical Service
Philipsburg, Pennsylvania, United States
Buxmont Cardiology Associates, PC
Sellersville, Pennsylvania, United States
Rhode Island Heart Failure Center
Providence, Rhode Island, United States
Charleston Cardiology
Charleston, South Carolina, United States
South Carolina Heart Center
Columbia, South Carolina, United States
Heart Specialists
Friendswood, Texas, United States
Texas Cardiac Center
Lubbock, Texas, United States
Intermountain Medical Center
Murray, Utah, United States
Heart Center
Salt Lake City, Utah, United States
Winchester Medical Center
Winchester, Virginia, United States
Luther Midelfort Mayo Health Systems
Eau Claire, Wisconsin, United States
Green Bay HeartCare
Green Bay, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9-13.
Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996 Dec 1;94(11):2793-9. doi: 10.1161/01.cir.94.11.2793.
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55. doi: 10.1056/NEJM199605233342101.
Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996 Dec 1;94(11):2800-6. doi: 10.1161/01.cir.94.11.2800.
Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail. 1997 Sep;3(3):173-9. doi: 10.1016/s1071-9164(97)90013-0.
Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May;25(6):1225-31. doi: 10.1016/0735-1097(95)00012-S.
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet. 1997 Feb 8;349(9049):375-80.
Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 1;94(11):2807-16. doi: 10.1161/01.cir.94.11.2807.
Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001 May 5;357(9266):1385-90. doi: 10.1016/s0140-6736(00)04560-8.
Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez-Sendon J, Sharpe N; CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004 Jan 20;109(2):201-6. doi: 10.1161/01.CIR.0000108928.25690.94. Epub 2004 Jan 5.
Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol. 1997 Apr;29(5):1060-6. doi: 10.1016/s0735-1097(97)00012-0.
Greenberg BH, Mehra M, Teerlink JR, Ordronneau P, McCollum D, Gilbert EM. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. Am J Cardiol. 2006 Oct 2;98(7A):53L-59L. doi: 10.1016/j.amjcard.2006.08.003. Epub 2006 Aug 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
104852
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.